Impax Asset Management Group plc bought a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,916 shares of the medical research company’s stock, valued at approximately $2,032,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Trust Co. of Vermont acquired a new stake in shares of Natera in the 2nd quarter valued at approximately $26,000. IFG Advisory LLC bought a new stake in shares of Natera during the 3rd quarter valued at approximately $40,000. Elevation Wealth Partners LLC bought a new stake in shares of Natera during the 2nd quarter valued at approximately $30,000. Continuum Advisory LLC acquired a new position in Natera during the 2nd quarter worth approximately $33,000. Finally, Rakuten Securities Inc. acquired a new position in Natera during the 2nd quarter worth approximately $35,000. Institutional investors own 99.90% of the company’s stock.
Analyst Ratings Changes
NTRA has been the subject of several research reports. UBS Group increased their price objective on shares of Natera from $290.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. Stephens raised their target price on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. JPMorgan Chase & Co. decreased their target price on shares of Natera from $460.00 to $405.00 and set an “overweight” rating on the stock in a research note on Friday, November 6th. Wells Fargo & Company boosted their target price on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Finally, Piper Sandler reiterated an “overweight” rating and set a $363.50 price target on shares of Natera in a report on Friday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $394.31.
Check Out Our Latest Analysis on Natera
Insider Activity at Natera
In related news, CFO Michael Brophy sold 1,906 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $425.55, for a total value of $811,098.30. Following the completion of the transaction, the chief financial officer owned 46,574 shares in the company, valued at $19,819,565.70. This trade represents a 3.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 15,160 shares of Natera stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the sale, the insider owned 110,859 shares in the company, valued at approximately $36,238,698.51. This represents a 12.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 47,056 shares of company stock worth $17,760,989 in the last quarter. 5.05% of the stock is owned by insiders.
Natera Trading Up 0.7%
Natera stock opened at $289.50 on Thursday. The stock has a 50-day moving average price of $377.35 and a two-hundred day moving average price of $272.44. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The company has a market capitalization of $41.98 billion, a PE ratio of -253.95 and a beta of 1.55.
Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The firm had revenue of $793.98 million for the quarter, compared to the consensus estimate of $707.54 million. Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. The business’s revenue for the quarter was up 34.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.64) earnings per share. As a group, analysts predict that Natera, Inc. will post -1.25 earnings per share for the current fiscal year.
Natera Company Profile
Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
Further Reading
- Five stocks we like better than Natera
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
